Clinical Trial Update: Driving Performance After Middle of the Night Administration of 3.5 mg Zolpidem Tartrate Sublingual Tablet [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating driving performance after middle-of-the-night administration of 3.5 mg zolpidem tartrate sublingual tablet in individuals with insomnia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• Zolpidem tartrate sublingual tablet 3.5 mg (zolpidem tartrate)

Snippet

Sponsor: Transcept Pharmaceuticals | Conditions: Insomnia | Phase 1 | Status: COMPLETED | Results posted: 2012-01-20